Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash Flows From Operating Activities    
Net loss $ (2,583,433) $ (3,155,874)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 6,334 6,334
Amortization of right-of-use assets 55,012
Amortization of debt issuance costs 64,841
Amortization of intangible asset 596,496 422,814
Deferred income tax benefit (442,152) (771,332)
Stock-based compensation 394,164 50,528
Payments made by an investor in satisfaction of their stock subscription receivable 900,000
Net changes in operating assets and liabilities:    
Prepaid expenses 37,552 (240,872)
Operating lease liability (58,999)
Accrued interest 8,587 89,522
Accounts payable (227,241) 29,334
Due (from)/to related parties 46,647 (32,393)
Accrued expenses 30,374 293,160
Net cash used in operating activities (1,236,659) (3,243,938)
Cash Flows From Investing Activities    
Purchase of intangible asset (1,782)
Purchase of software license (20,500)
Net cash used in investing activities (22,282)
Cash Flows From Financing Activities    
Net proceeds from issuance of common stock 2,965,095
Transaction costs incurred on Senior Convertible Notes (4,742)
Payment of placement agent and legal fees associated with clinical funding commitment (117,339)
Net cash provided by financing activities 2,843,014
Net (Decrease)/Increase in Cash and Cash Equivalents (1,236,659) (423,206)
Cash and Cash Equivalents - Beginning of Period 1,740,961 2,847,429
Cash and Cash Equivalents - End of Period 504,302 2,424,223
Non-Cash Investing and Financing Activities:    
Right-of-use asset obtained in exchange for operating lease liability (293,198)
Reduction in deferred lease liability (9,963)
Operating lease liability 303,161
Recognize the exclusive license intangible asset acquired from CoNCERT (11,037,147)
Recognize deferred tax liability for basis difference for Intangible asset   3,037,147
Recognize additional paid-in capital for consideration paid from the transfer of 2,090,301 common shares of Processa released by Promet to CoNCERT for Processa 8,000,000
Net
Conversion of $230,000 and $2,350,000 (respectively) of Senior Convertible Debt and related accrued interest into 126,741 and 1,206,245 shares (respectively) of common stock and warrants 258,930 2,395,111
Common stock and stock purchase warrants (forfeited) issued in connection with a clinical trial funding commitment $ (900,000) $ 1,800,000